Contract Awards

Not specified

1731/2025- Acquisition Of U42- Ustecinumab [90 Mg; Sol Inj; Syringe] - Patients In Treatment, U41- Ustecinumab [45 Mg/ 0.5 Ml; Sol Inj; Syringe] - Patients In Treatment, U43- Ustecinumab [130 Mg; Sol Inj; Frs] - Patients In Treatment, U47- Ustecinumab [90 Mg/1 Ml; Sol Inj; Pen] Patients Under Treatment And I287- Infliximab Patients Under Treatment [100 Mg; Powder P/A Conc To Sol P/A Perf; Frs].